Oct 19 (Reuters) – argenx SE: * TO PRESENT PHASE 3 ALKIVIA RESULTS IN AUTOIMMUNE MYOSITIS AS A LATE-BREAKING ORAL PRESENTATION AT ACR CONVERGENCE 2026 * ALKIVIA PROVIDES FIRST PHASE 3 EVIDENCE THAT
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
By Stephen Nellis SAN FRANCISCO, Oct 19 (Reuters) - Nvidia has won central processor chip…
Spread across 1 lakh sq ft, the facility brings Ayurvedic consultations, Panchakarma, inpatient care and…
WASHINGTON, Oct 19 (Reuters) - US homebuilder sentiment plunged to the lowest level in nearly…
By Shashwat Chauhan Oct 19 (Reuters) - AI-linked stocks bounced back on Monday after a…
Oct 19 (Reuters) - * ANTHROPIC READIES MODEL THAT READS USERS' INTENTIONS BETTER - THE…
* Philadelphia chips index set to snap longest losing streak since 2008 * CoreWeave jumps…